around vutrisiran. where good the ATTR start we’re associated multiple and is our with Tolga, currently with and Also to I’ll ATTR morning, product advancing in amyloidosis. candidates, the Thanks, approved in treat efforts markets hereditary amyloidosis, two polyneuropathy late-stage ONPATTRO world clinical everyone. patisiran
the amyloidosis patients. expanding label product’s study ATTR middle to year. of of cardiomyopathy To we the expect end, for treatment results are conducting to this we wild-type with, this in report committed X APOLLO-B hereditary Phase which line top in the the and We’re both
in we’re injection vutrisiran, exciting the Stargardt advancing ATTR, by is In which conducting also as a We’re development opportunity as ATTR disease. also for announced is Phase studies. delivered newly and X two subcutaneous quarterly in amyloidosis well
basis for nine submissions the its evaluating is PDUFA endpoints we from In XXXX. an primary our EMA, FDA We with showed in results polyneuropathy. positive to with hATTR and HELIOS-A U.S. forward upcoming the both study. the regulatory with of safety and The approval to These acceptable months secondary vutrisiran met first study data profile. presented of potential a nine-month amyloidosis XXXX, April the we XX, form and the look date
Additionally, the presented just we from XX-month a positive the few results endpoints weeks full ago, for the study.
TTR once enrolled weeks months. HELIOS-A months kg were a polyneuropathy. study of patisiran in of To comparator. to XXX administered milligrams reduction receive who X.X with at mg a dose is a was rapid dose every sustained open-label The subcutaneously study patients XX a intravenously or three group once hereditary every vutrisiran as serum at ATTR the period per administered and a reminder, in of reference start, amyloidosis XX X:X vutrisiran patients a over randomized randomized in As three
a steady-state Specifically, mean serum baseline vutrisiran reduction XX%. TTR from of achieved
also over to low variability see reduction interpatient very pleased We’re in time the TTR period.
of would vutrisiran TTR patisiran was TTR vutrisiran clinical level statistically observed reduction achieved to the is impact. should but arm. of in a reduction This and the expected, a level reference with result we by that comparable non-inferior patisiran comparable important as expect, in As
HELIOS-A especially This, evaluated of course, statistically endpoints data evidence speed, in Neuropathy significant as that confidence improvements and the relative of including of at treatment neuropathy and XX the quite at We’re an gait months, our with external vutrisiran. mNIS+X, of result measured Phase manifestations met modified with Score, from APOLLO APOLLO-B effect cardiac life, similar disability status patisiran the nutritional to in or and overall observations, underscore measured Looked by ongoing delighted placebo amyloidosis with data vutrisiran end well to of as quality and of the months cardiac to improvement study and in including as secondary array vutrisiran is to demonstrated in expected, the is to HELIOS-B all providing parameters being aggregate potentially vutrisiran the trend imaging, to patisiran. in cardiac extend the the on cardiomyopathy. suggest These as may disease. endpoint both Phase of improvement baseline compared cardiac collectively technetium vutrisiran also compared placebo the improvement improvement at treatment in NT-proBNP X across ATTR points update X exploratory that of in patisiran. XX XX in in Furthermore, studies, patisiran scintigraphy potential towards months, with at exploratory Impairment observed echocardiographic
emergent lower and in dizziness, in at diarrhea, an to unrelated with adverse concerns. which serious all – study pain month at to arthralgia, and occurred by there tract by These to X.X% safety edema, rate the reactions study Vutrisiran two the events of in included urinary related compared and related XX consisting nine The single or external three related reported There site arthralgia dyslipidemia By two events. events extremity of placebo. occurring Let’s and four each urinary since tract the mild of with months. demonstrated arm hepatic now deaths, these with investigator. were similar patients by and were or XX that occurred discontinued considered of by profile encouraging deaths transient have in patients adverse considered safety were review month pain failure infection. was of XX% to the event neither new infection, drug been cardiac drug. tolerability investigators five exception Injection vutrisiran peripheral reported. deemed a nine Treatment extremity, relative and no were of or study month was events patients due XX, study in results more X.X% SAEs on discontinuation or and the month all as the vutrisiran adverse safety previously the
We’re very of around pleased that evolve. on totality patients hATTR amyloidosis exciting an We results vutrisiran for the vutrisiran, data, to these if and providing with continues believe with attractive present with the approved, the will profile that opportunity, option polyneuropathy of commercial treatment world. based the an
complete HELIOS-B mortality endpoint strong will design CV The over events XX-month course, from this APOLLO-B Of for study, has We we and vutrisiran outcome following amyloidosis vutrisiran, of Phase regulatory for expect authorities. just consider X ongoing early study of third potential wild-type well the HELIOS-B, a this and and to results patients, with we another XXXX. with due ahead analysis, includes ATTR in our cardiac conducting X study in and enrollment study also and excited XXXX which with XXX start is is in an enrollment. interim we’re results the the quarter with all-cause engagement to Phase of and were hereditary the schedule full cardiomyopathy. the
toxic reducing a As of therapies eye We for in that disease. for of unmet stems medical the an in disease. metabolites to Stargardt believe the promising in progressive vutrisiran important a to Stargardt to an we intend realization start potential expand use I of reduce our that vutrisiran inherited vutrisiran and represents action treat in late exist in area those in study the lead announced earlier, the to this the can alluded near-term XXXX. loss providing buildup A, potentially of vision expansion turn today. recently also mechanism from disease, new Phase ocular to We vutrisiran opportunity This vitamin via need high X where opportunity an
programs, making with late-stage addition programs. clinical we believe and been our In we’ve also mid-stage our to early great progress
expansion for highlighted into we’ve driver beyond rare As for a now, growth our is key a bit diseases disease. Alnylam prevalent
Our a is the example. the as angiotensinogen program the for in hypertension evaluated X of RNAi validated KARDIA program. our in Zilebesiran, ALN-AGT, is therapeutic target Zilebesiran genetically formerly Phase for investigational is great development being targeting known treatment hypertension.
safety moderate to patients with the The KARDIA-X X the as efficacy first of monotherapy of and zilebesiran designed studies, evaluate is a enrolling currently in and to hypertension. is mild
add-on these The of treatment despite quarter fourth second hypertension is in the was and studies to patients the KARDIA-X, of evaluate initiated and in with designed of efficacy care. safety therapy zilebesiran as standard with an
from We Scientific Heart updated study also data gather presented continue X to and recently Phase the Association at data Sessions. American the ongoing
dosing. through resulted reductions AGT in doses and single zilebesiran of six sustained blood supporting months, Here, investigational pressure potentially biannual and quarterly
to no also pharmacology zilebesiran low We with that of pressure augmented pharmacodynamic observed response the salt adverse under blood reported. intake events consistent hypotensive peak with effect cardiac was
renal toxicity. supporting without additional no serious adverse with development. signals events withdrawals of treatment-related Irbesartan Zilebesiran or lowering continued well tolerated blood with in study was coadministration pressure result Additionally, generally
for will the Another sustainable Alnylam come be in organic product driver innovation. driving key engine to years our growth
two the amyloid Here, treatment We CTA with we disease filings quarter. and for recent CNS ALN-APP, for angiopathy. very fourth in made ALN-XDH excitingly, programs in Alzheimer’s our cerebral potential the the towards strong program, first and gout, of progress moved clinic
the forward X programs Phase for There announce study many starting year. date the now just X we Phase for over you Jeff engine, to being We’re been updating turn that milestones. ALN-XDH on the amongst and thrilled year. financial to look a has initiated, to and highlights Jeff? our research me upcoming forward progress early to that, and results call now our trial few look exciting With advanced we the are let review this ALN-APP by the throughout organic all this to
